{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:54:10Z","timestamp":1793879650322,"version":"4.7.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jacadv.2024.101568","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T14:52:57Z","timestamp":1737211977000},"page":"101568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Accuracy of Established Prognostic Staging Systems for Cardiac Transthyretin Amyloidosis in the Tafamidis Era"],"prefix":"10.1016","volume":"4","author":[{"given":"Maximilian Leo","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Spethmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Messroghli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-0347","authenticated-orcid":false,"given":"Anna","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8455-3750","authenticated-orcid":false,"given":"Isabel","family":"Mattig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3811-7920","authenticated-orcid":false,"given":"Bettina","family":"Heidecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jacadv.2024.101568_bib1","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101568_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.jacadv.2024.101568_bib3","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2024.101568_bib4","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"11","key":"10.1016\/j.jacadv.2024.101568_bib5","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American college of cardiology solution set oversight committee","volume":"81","author":"Writing","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"30","key":"10.1016\/j.jacadv.2024.101568_bib6","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacadv.2024.101568_bib7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacadv.2024.101568_bib8","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacadv.2024.101568_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.jacadv.2024.101568_bib10","first-page":"424","article-title":"Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis: direct comparison of two staging systems","volume":"36","author":"Cappelli","year":"2020","journal-title":"Can J Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2024.101568_bib11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101568_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-Term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10.1016\/j.jacadv.2024.101568_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2018-10-875252","article-title":"Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay","volume":"133","author":"Muchtar","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.jacadv.2024.101568_bib14","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.jacadv.2024.101568_bib15","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2024.101568_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102172","article-title":"Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis","volume":"63","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"14","key":"10.1016\/j.jacadv.2024.101568_bib17","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood-2010-02-267708","article-title":"Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay","volume":"116","author":"Kristen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jacadv.2024.101568_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/heartjnl-2013-304957","article-title":"High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis","volume":"100","author":"Dispenzieri","year":"2014","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101568_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2023.12.006","article-title":"Cardiac troponin in patients with light chain and transthyretin cardiac amyloidosis: JACC: CardioOncology state-of-the-art review","volume":"6","author":"De Michieli","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1016\/j.jacadv.2024.101568_bib20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00392-019-01559-y","article-title":"A\u00a0novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis","volume":"109","author":"Kreusser","year":"2020","journal-title":"Clin Res Cardiol"},{"issue":"21","key":"10.1016\/j.jacadv.2024.101568_bib21","first-page":"4868","article-title":"Prognostic value of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment","volume":"10","author":"Oghina","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1016\/j.jacadv.2024.101568_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jacadv.2024.101568_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"10","key":"10.1016\/j.jacadv.2024.101568_bib24","article-title":"Cardiac biomarker change at 1 Year after tafamidis treatment and clinical outcomes in patients with transthyretin amyloid cardiomyopathy","volume":"13","author":"Kuyama","year":"2024","journal-title":"J\u00a0Am Heart Assoc"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24008494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24008494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:15:38Z","timestamp":1768965338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X24008494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2772963X24008494"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101568","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accuracy of Established Prognostic Staging Systems for Cardiac Transthyretin Amyloidosis in the Tafamidis Era","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101568"}}